Checchi Capital Advisers LLC lessened its stake in Edwards Lifesciences Corp (NYSE:EW) by 9.1% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,802 shares of the medical research company’s stock after selling 181 shares during the quarter. Checchi Capital Advisers LLC’s holdings in Edwards Lifesciences were worth $340,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in EW. Columbia Trust Co 01012016 lifted its stake in shares of Edwards Lifesciences by 1.1% in the 1st quarter. Columbia Trust Co 01012016 now owns 4,264 shares of the medical research company’s stock valued at $803,000 after acquiring an additional 47 shares during the last quarter. Coastal Investment Advisors Inc. grew its stake in shares of Edwards Lifesciences by 13.5% in the 4th quarter. Coastal Investment Advisors Inc. now owns 454 shares of the medical research company’s stock valued at $110,000 after buying an additional 54 shares during the period. Intrust Bank NA boosted its stake in Edwards Lifesciences by 0.8% during the 4th quarter. Intrust Bank NA now owns 6,682 shares of the medical research company’s stock valued at $1,559,000 after purchasing an additional 55 shares during the last quarter. Valeo Financial Advisors LLC boosted its stake in Edwards Lifesciences by 12.1% during the 1st quarter. Valeo Financial Advisors LLC now owns 528 shares of the medical research company’s stock valued at $113,000 after purchasing an additional 57 shares during the last quarter. Finally, Cedar Brook Financial Partners LLC lifted its position in shares of Edwards Lifesciences by 2.3% during the 1st quarter. Cedar Brook Financial Partners LLC now owns 2,529 shares of the medical research company’s stock worth $477,000 after buying an additional 57 shares in the last quarter. Hedge funds and other institutional investors own 82.69% of the company’s stock.

A number of research analysts recently weighed in on EW shares. BTIG Research reiterated a “hold” rating on shares of Edwards Lifesciences in a research note on Thursday, April 23rd. Canaccord Genuity reaffirmed a “buy” rating on shares of Edwards Lifesciences in a research note on Friday, April 24th. Wells Fargo & Co downgraded shares of Edwards Lifesciences from an “overweight” rating to an “equal weight” rating and decreased their price target for the stock from $250.00 to $230.00 in a research note on Tuesday, April 28th. Raymond James upped their price objective on shares of Edwards Lifesciences from $230.00 to $250.00 and gave the stock an “outperform” rating in a report on Friday, April 24th. Finally, Goldman Sachs Group started coverage on shares of Edwards Lifesciences in a research report on Wednesday, February 12th. They set a “neutral” rating and a $253.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and sixteen have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $247.52.

NYSE:EW opened at $212.96 on Friday. The firm has a 50-day simple moving average of $209.86 and a 200-day simple moving average of $223.05. The company has a debt-to-equity ratio of 0.17, a quick ratio of 2.47 and a current ratio of 3.36. Edwards Lifesciences Corp has a one year low of $154.52 and a one year high of $247.64. The firm has a market cap of $44.92 billion, a P/E ratio of 40.72, a P/E/G ratio of 2.74 and a beta of 0.85.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, April 23rd. The medical research company reported $1.51 earnings per share for the quarter, topping the consensus estimate of $1.29 by $0.22. The company had revenue of $1.13 billion for the quarter, compared to the consensus estimate of $1.03 billion. Edwards Lifesciences had a net margin of 24.71% and a return on equity of 31.83%. Edwards Lifesciences’s revenue was up 13.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.32 EPS. On average, research analysts predict that Edwards Lifesciences Corp will post 4.95 EPS for the current fiscal year.

In other news, CEO Michael A. Mussallem sold 22,850 shares of the company’s stock in a transaction on Tuesday, April 7th. The shares were sold at an average price of $202.34, for a total value of $4,623,469.00. Following the sale, the chief executive officer now directly owns 69,976 shares of the company’s stock, valued at approximately $14,158,943.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 4,358 shares of the company’s stock in a transaction on Friday, May 15th. The shares were sold at an average price of $215.16, for a total transaction of $937,667.28. Following the completion of the sale, the vice president now directly owns 28,609 shares in the company, valued at $6,155,512.44. The disclosure for this sale can be found here. In the last three months, insiders have sold 96,661 shares of company stock worth $20,246,793. 1.48% of the stock is owned by insiders.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

Featured Article: How a Strangle Strategy is different from a Straddle Strategy

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.